Ketamine Versus Etomidate for Emergency Tracheal Intubation

visual bubble
visual bubble
visual bubble
visual bubble
Jeffrey T. Pepin, MD, FACEP, FAAEM, FASE James H. Lantry III, MD
11/17/2026

This Concise Critical Appraisal reviews the Randomized Trial of Sedative Choice for Intubation, which compared ketamine and etomidate for emergency tracheal intubation in critically ill adults. The trial found no significant difference in mortality between the two agents but a higher incidence of cardiovascular collapse with ketamine.
 
Emergency tracheal intubation is a high-risk procedure. In the Impact and Best Practices of Airway Management in Critically Ill Patients study, 45.2% of critically ill patients experienced at least one major peri-intubation adverse event, most commonly cardiovascular instability.1 Because nearly every patient receives an induction medication, the choice of sedative is a potentially modifiable factor in this risk.

For years, concern has centered on etomidate because even a single dose suppresses adrenal cortisol production. Whether this physiologic effect causes clinically meaningful harm remains uncertain. Previous randomized trials have not shown a consistent difference in mortality between etomidate and ketamine, and a recent meta-analysis found low-certainty evidence of no difference in mortality between the agents.2,3

The Randomized Trial of Sedative Choice for Intubation (RSI) trial sought a more definitive answer.4 Investigators randomized 2365 critically ill adults undergoing emergency tracheal intubation at 14 emergency departments and intensive care units (ICUs) across six U.S. medical centers to receive either ketamine or etomidate. Patients primarily presenting with trauma were excluded. The primary outcome was in-hospital death by day 28. The prespecified secondary outcome was cardiovascular collapse during intubation, defined as systolic blood pressure below 65 mm Hg, new or increased vasopressor use, or cardiac arrest.

The study population was severely ill: 46.7% had sepsis or septic shock, 22% were already receiving vasopressors, and more than half were intubated in the emergency department. The median ketamine and etomidate doses were 1.6 mg/kg and 0.28 mg/kg, respectively.

Mortality rates were nearly identical. In-hospital death by 28 days occurred in 28.1% of patients receiving ketamine and 29.1% receiving etomidate (adjusted absolute risk difference, ‒0.8 percentage points; 95% CI, ‒4.5 to 2.9; P = 0.65). Among patients with sepsis, mortality rates were also similar: 38.8% with ketamine and 38.2% with etomidate.

The cardiovascular findings were more surprising. Cardiovascular collapse occurred in 22.1% of patients receiving ketamine, compared with 17.0% receiving etomidate, an absolute difference of 5.1 percentage points (95% CI, 1.9 to 8.3). In subgroup analyses, rates were 30.6% versus 20.9% among patients with sepsis and 31.4% versus 20.7% among those with an Acute Physiology and Chronic Health Evaluation II score of 20 or higher.

Ketamine's sympathomimetic effects may support blood pressure, but direct negative inotropic effects can emerge when adrenergic support is blunted and may become clinically relevant in critically ill patients with limited catecholamine reserve.5,6

Several limitations are important. The trial was unblinded, patients with primary trauma were excluded, and the comparison does not address other induction agents. Subgroup estimates should be interpreted cautiously because their confidence intervals were not adjusted for multiplicity. In addition, the median ketamine dose was close to a traditional induction dose; whether greater dose reduction in patients with severe shock would alter the cardiovascular findings remains unknown.

The RSI trial substantially strengthens the evidence on induction-agent selection for emergency intubation. Despite long-standing concern about adrenal suppression, ketamine did not reduce in-hospital mortality compared with etomidate, even among patients with sepsis.

Just as important, ketamine should not be assumed to be the more hemodynamically protective option for critically ill patients. Cardiovascular collapse occurred more often with ketamine in the overall trial.

These findings should make clinicians more comfortable using etomidate when appropriate and more cautious when assuming ketamine protects against peri-intubation hypotension. Ultimately, preventing cardiovascular collapse likely depends less on selecting a single “best” induction medication and more on recognizing physiologic risk, optimizing hemodynamics before induction, preparing vasopressors, and titrating medication doses to the patient's physiologic reserve. 


References
  1. Russotto V, Myatra SN, Laffey JG, et al; INTUBE Study Investigators. Intubation practices and adverse peri-intubation events in critically ill patients from 29 countries. JAMA. 2021;325(12):1164-1172.
  2. Jabre P, Combes X, Lapostolle F, et al; KETASED Collaborative Study Group. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet. 2009;374(9686):293-300.
  3. Greer A, Hewitt M, Khazaneh PT, et al. Ketamine versus etomidate for rapid sequence intubation: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2025;53(2):e374-e383.
  4. Casey JD, Seitz KP, Driver BE, et al. Ketamine or etomidate for tracheal intubation of critically ill adults. N Engl J Med. 2026;394(16):1608-1620.
  5. Hanouz JL, Persehaye E, Zhu L, et al. The inotropic and lusitropic effects of ketamine in isolated human atrial myocardium: the effect of adrenoceptor blockade. Anesth Analg. 2004;99(6):1689-1695.
  6. Waxman K, Shoemaker WC, Lippmann M. Cardiovascular effects of anesthetic induction with ketamine. Anesth Analg. 1980;59(5):355-358.
 

Jeffrey T. Pepin, MD, FACEP, FAAEM, FASE
Author
Jeffrey T. Pepin, MD, FACEP, FAAEM, FASE
Jeffrey T. Pepin, MD, FACEP, FAAEM, FASE, is a professor in the Division of Critical Care, Department of Anesthesiology, at the University of Minnesota Medical School in Minneapolis, Minnesota, USA. Dr. Pepin serves as director of critical care ultrasound and leads educational initiatives in advanced airway management, resuscitation, and critical care ultrasound across the university’s adult critical care fellowship programs.
James H. Lantry III, MD
Author
James H. Lantry III, MD
James H. Lantry III, MD, is the associate director of quality and critical care at Inova Fairfax Hospital and an adjunct assistant professor of medicine and critical care medicine at the University of Maryland School of Medicine in Baltimore, Maryland, USA. Dr. Lantry is an editor of Concise Critical Appraisal.
Knowledge Area:

Recent Blog Posts

^